In first, FDA approves KRAS-blocking cancer drug from Amgen

In first, FDA approves KRAS-blocking cancer drug from Amgen

Lumakras is the first drug proven effective in targeting the KRAS gene, which is often mutated in lung, colon and pancreatic cancers. Amgen will charge $17,900 per month for Lumakras at list price, which doesn't account for rebates or discounts that may be offered to insurers.